SEC Form	4
----------	---

## FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden

hours per response:

0.5

Check this box if no longer subject to	
Section 16. Form 4 or Form 5	
obligations may continue. See	
Instruction 1(b).	

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

			01 5		ivesiment Cor	ilpany Act of 1940						
1. Name and Address of Reporting Person* Cajigas John (Last) (First) (Middle) C/O TANDEM DIABETES CARE, INC., 11045 ROSELLE STREET		<u>TAN</u>	uer Name <b>and</b> Ticke <u>NDEM DIAB</u> te of Earliest Transa 3/2013	ETES CĂ	<u>RE INC</u> [ TNDM ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner X Officer (give title Other (specify below) below) CHIEF FINANCIAL OFFICER						
11045 ROSELLE STREET       (Street)       SAN DIEGO     CA       (City)     (State)       (Zip)			4. If A	mendment, Date of	Original Filed	(Month/Day/Year)	<ul> <li>6. Individual or Joint/Group Filing (Check Applicable Line)</li> <li>X Form filed by One Reporting Person</li> <li>Form filed by More than One Reporting Person</li> </ul>					
		Table I - Nor	n-Derivative	Securities Acq	uired, Dis	posed of, or Benefi	cially (	Owned				
1 Title of Coourity	(Instr 2)		2 Transaction	24 Deemed	2	4 Securities Acquired (A)	or	E Amount of	6 Ownership	7 Nature of		

Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)		Transaction Code (Instr.					Securities Beneficially Owned Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership	
			Code	v	Amount	(A) or (D)	Price	<ul> <li>Reported Transaction(s) (Instr. 3 and 4)</li> </ul>		(Instr. 4)	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code ( 8)		Derivative		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		Transaction(s) (Instr. 4)		
Stock Option <sup>(1)</sup>	\$15	11/13/2013		A		191,000		(2)	(3)	Common Stock	191,000	\$0.00	191,000	D	

Explanation of Responses:

1. Granted pursuant to the Issuer's Tandem Diabetes Care, Inc. 2013 Stock Incentive Plan.

2. All shares subject to the option will vest as to 25% on 11/13/2014 and the remainder in 36 equal monthly installments thereafter.

3. The expiration date for these options is 10 years from the date of grant.

## **Remarks:**

/s/ David B. Berger, Attorneyin-Fact for John Cajigas

11/14/2013

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.